A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Status:
RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.
The name of the study drug involved in this research study is:
-Troriluzole (a tripeptide prodrug of riluzole)
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Ugonma Chukwueke
Collaborators:
Biohaven Pharmaceuticals, Inc. National Institutes of Health (NIH)